First-Line Tyrosine Kinase Inhibitor With or Without Aggressive Upfront Local Radiation Therapy In Patients With EGFRm Oligometastatic Non-Small-Cell Lung Cancer: Interim Results of A RandomizedPhase III, Open-Label ClinicalTrial (SINDAS) (NCT02893332).

Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients : a multicenter, single arm, phase II clinical trial

CANOPY-N: A Phase II Study of Canakinumab (CAN) or Pembrolizumab (PEM) as Monotherapy or in Combination as Neoadjuvant Therapy in Patients (Pts) with Surgically Resected (Stage IB-IIIA) Non-Small Cell Lung Cancer (NSCLC)

Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated interim results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

Is first line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2) safe? An interim analysis of the multicenter, single-arm SAKK phase II trial 19/17

A phase I clinical study to investigate the safety, tolerability and pharmacokinetics of PD-1 antibody Camrelizumab (SHR-1210) in patients with solid tumor: the results of Non-small cell lung cancer cohort.

Brigatinib (BRG) vs Crizotinib (CRZ) in the Phase 3 ALTA-1L Trial: Updated Results

Patient-reported Outcomes (PROs) From Patients with ROS1-positive (ROS1+) Non-small Cell Lung Cancer (NSCLC) Receiving Entrectinib in the Global Phase 2 STARTRK-2 Study

SGNLVA-005: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Lung Malignancies

AcceleRET Lung: A Phase 3 Study of Pralsetinib for First-Line Treatment of RET Fusion+ Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase II trial of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) harboring MET alterations: VISION study

Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small-cell lung cancer

Pembrolizumab for advanced mesothelioma: results from the phase 2 KEYNOTE-158 study